Status:

TERMINATED

Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Lymphoproliferative Disorder

Eligibility:

All Genders

Phase:

PHASE1

Brief Summary

RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treatin...

Detailed Description

OBJECTIVES: Primary * Determine the efficacy of photochemically-treated autologous Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell vaccine in generating an EBV-specific T-cell and antibod...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Being considered for a solid organ transplant
  • At high risk for post-transplant lymphoproliferative disorder
  • PATIENT CHARACTERISTICS:
  • Body weight ≥ 25 kg
  • Karnofsky performance status 50-100% OR
  • Lansky performance status 50-100%
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use contraception during and for 2 months after completion of study treatment
  • Hemoglobin ≥ 8 g/dL (erythropoietin allowed)
  • No history of autoimmune disease, including any of the following:
  • Systemic lupus erythematosus
  • Sarcoidosis
  • Rheumatoid arthritis
  • Glomerulonephritis
  • Vasculitis
  • No primary immunodeficiency
  • No HIV positivity
  • PRIOR CONCURRENT THERAPY:
  • No corticosteroids for 1 month before and for 1 month after the first study vaccination, except for the following:
  • Physiologic steroid dosing (≤ 20 mg/day of prednisone or steroid equivalent) for adrenal insufficiency
  • Inhaled steroids

Exclusion

    Key Trial Info

    Start Date :

    January 1 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2012

    Estimated Enrollment :

    23 Patients enrolled

    Trial Details

    Trial ID

    NCT00278200

    Start Date

    January 1 2003

    End Date

    August 1 2012

    Last Update

    April 25 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, United States, 21231-2410